Endo International PLC
F:EO7
Legen Sie fest, zu welchem Kurs Sie kaufen würden. Wir helfen Ihnen, bereit zu bleiben.
|
E
|
Endo International PLC
F:EO7
|
IE |
|
MINISO Group Holding Ltd
F:MIF
|
CN |
|
H
|
Headwater Exploration Inc
XMUN:C6V
|
CA |
|
P
|
Paccar Inc
F:PAE
|
US |
|
B
|
Barclays PLC
F:BCY2
|
UK |
|
P
|
Paychex Inc
F:PCX
|
US |
|
G
|
Glencore PLC
OTC:GLCNF
|
CH |
|
M
|
Microchip Technology Inc
XHAM:MCP
|
US |
|
Resmed Inc
OTC:RSMDF
|
US |
Endo International PLC
Endo International PLC ist ein spezialisiertes Pharmaunternehmen, das an der Schnittstelle von Innovation und Notwendigkeit im Gesundheitswesen tätig ist. Das Kerngeschäft umfasst die Entwicklung, Herstellung und Vermarktung sowohl markengebundener als auch generischer pharmazeutischer Produkte. Endo baut auf einem diversifizierten Portfolio auf, das zahlreiche therapeutische Bereiche abdeckt, darunter Schmerztherapie, Urologie, Orthopädie und Endokrinologie. Das Unternehmen positioniert sich strategisch durch die Ansprache ungedeckter medizinischer Bedürfnisse, wobei häufig Nischenmärkte ins Visier genommen werden, in denen der Wettbewerb begrenzt ist und die so Premium-Preise und robuste Gewinnmargen ermöglichen. Die Einnahmequellen von Endo werden durch eine Mischung aus proprietären und generischen Arzneimitteln getragen, wobei ein bedeutender Anteil von bekannten Marken wie PERCOCET® und SUPPRELIN® LA stammt. Die Generikasparte ergänzt dies durch die Herstellung kosteneffizienter Versionen gängiger Medikamente, fördert die Marktverfügbarkeit und spricht kostenempfindliche Patienten sowie Leistungserbringer im Gesundheitswesen an. Durch die Nutzung seiner Forschungs- und Entwicklungskapazitäten erweitert Endo kontinuierlich sein Produktportfolio und erschließt neue Marktchancen. Das Wachstum des Unternehmens gründet auf seiner Fähigkeit, sich an die sich ständig wandelnde regulatorische Landschaft anzupassen, seine Abläufe effizient zu optimieren und strategische Partnerschaften einzugehen, die seine Marktreichweite erhöhen.
Endo International PLC ist ein spezialisiertes Pharmaunternehmen, das an der Schnittstelle von Innovation und Notwendigkeit im Gesundheitswesen tätig ist. Das Kerngeschäft umfasst die Entwicklung, Herstellung und Vermarktung sowohl markengebundener als auch generischer pharmazeutischer Produkte. Endo baut auf einem diversifizierten Portfolio auf, das zahlreiche therapeutische Bereiche abdeckt, darunter Schmerztherapie, Urologie, Orthopädie und Endokrinologie. Das Unternehmen positioniert sich strategisch durch die Ansprache ungedeckter medizinischer Bedürfnisse, wobei häufig Nischenmärkte ins Visier genommen werden, in denen der Wettbewerb begrenzt ist und die so Premium-Preise und robuste Gewinnmargen ermöglichen.
Die Einnahmequellen von Endo werden durch eine Mischung aus proprietären und generischen Arzneimitteln getragen, wobei ein bedeutender Anteil von bekannten Marken wie PERCOCET® und SUPPRELIN® LA stammt. Die Generikasparte ergänzt dies durch die Herstellung kosteneffizienter Versionen gängiger Medikamente, fördert die Marktverfügbarkeit und spricht kostenempfindliche Patienten sowie Leistungserbringer im Gesundheitswesen an. Durch die Nutzung seiner Forschungs- und Entwicklungskapazitäten erweitert Endo kontinuierlich sein Produktportfolio und erschließt neue Marktchancen. Das Wachstum des Unternehmens gründet auf seiner Fähigkeit, sich an die sich ständig wandelnde regulatorische Landschaft anzupassen, seine Abläufe effizient zu optimieren und strategische Partnerschaften einzugehen, die seine Marktreichweite erhöhen.
Geschäftsleitung
Blaise A. Coleman is a seasoned business executive known for his leadership at Endo International PLC, a specialty pharmaceutical company. Coleman began his tenure at Endo in 2006 and has held various positions of increasing responsibility. Before becoming the company's Chief Executive Officer (CEO), he served as the Executive Vice President and Chief Financial Officer (CFO). In his role as CFO, Coleman was instrumental in overseeing the financial operations of the company, guiding Endo through various financial strategies, capital allocation, and cost management programs. As CEO, Coleman focused on restructuring the company to enhance its operational efficiency and competitive position in the pharmaceutical industry. His tenure was marked by efforts to streamline operations, optimize the company's portfolio, and navigate complex market dynamics, including regulatory challenges and shifts in healthcare policies. Before joining Endo, Coleman held roles in financial management and oversight in other organizations, which helped build his expertise in corporate finance and strategic planning. His leadership is characterized by a commitment to driving sustainable growth while prioritizing innovation and customer satisfaction. Overall, Coleman has played a crucial role in shaping Endo's strategic direction, working to improve its financial performance and operational resilience in a challenging industry landscape.
As CEO, Coleman focused on restructuring the company to enhance its operational efficiency and competitive position in the pharmaceutical industry. His tenure was marked by efforts to streamline operations, optimize the company's portfolio, and navigate complex market dynamics, including regulatory challenges and shifts in healthcare policies.
Before joining Endo, Coleman held roles in financial management and oversight in other organizations, which helped build his expertise in corporate finance and strategic planning. His leadership is characterized by a commitment to driving sustainable growth while prioritizing innovation and customer satisfaction.
Overall, Coleman has played a crucial role in shaping Endo's strategic direction, working to improve its financial performance and operational resilience in a challenging industry landscape.
Matthew Joseph Maletta serves as the Executive Vice President and Chief Legal Officer at Endo International PLC. In his role, Maletta oversees the company's global legal strategies and is responsible for managing Endo's legal department, ensuring compliance with regulatory requirements, handling litigation and intellectual property matters, and advising the executive team on legal implications of business decisions. Before joining Endo, Maletta had extensive experience in the pharmaceutical industry. He served as the Vice President, Associate General Counsel, and Secretary at Allergan plc, where he played a critical role in various acquisitions, corporate governance, and legal affairs. His expertise extends to overseeing legal teams, managing complex legal challenges, and driving strategic initiatives aligned with corporate objectives. Maletta holds a law degree from a reputable institution and has built a career marked by legal acumen and leadership in the healthcare and pharmaceutical sectors. His contributions to Endo International PLC are significant in maintaining its legal integrity and supporting its business operations globally.
Before joining Endo, Maletta had extensive experience in the pharmaceutical industry. He served as the Vice President, Associate General Counsel, and Secretary at Allergan plc, where he played a critical role in various acquisitions, corporate governance, and legal affairs. His expertise extends to overseeing legal teams, managing complex legal challenges, and driving strategic initiatives aligned with corporate objectives.
Maletta holds a law degree from a reputable institution and has built a career marked by legal acumen and leadership in the healthcare and pharmaceutical sectors. His contributions to Endo International PLC are significant in maintaining its legal integrity and supporting its business operations globally.
Dr. James Patrick Tursi, M.D., is a seasoned professional in the pharmaceutical and healthcare industry. He has served as the Executive Vice President, Global Research & Development, and Chief Medical Officer at Endo International PLC, a company known for its development and distribution of pharmaceutical products. Dr. Tursi has an extensive background in medicine and pharmaceutical development. He completed his undergraduate studies at St. Joseph’s University, earning a Bachelor of Science degree in biology. He went on to obtain his medical degree from Drexel University College of Medicine and completed his residency in obstetrics and gynecology at Lehigh Valley Hospital. With a strong clinical foundation, Dr. Tursi transitioned into the pharmaceutical industry, where he brought his medical expertise to various leadership roles. Before joining Endo International, he held significant positions at companies like Aralez Pharmaceuticals, where he was the Chief Medical Officer. He also worked with companies such as Innocoll Holdings PLC and Auxilium Pharmaceuticals in key roles that involved clinical development, medical affairs, and strategic planning. Dr. Tursi is recognized for his contributions to advancing medical research and development across different therapeutic areas. His leadership at Endo International focuses on driving innovation and overseeing the company's medical and clinical development strategies. His professional journey reflects a commitment to enhancing patient care through the development of effective pharmaceutical solutions.
Dr. Tursi has an extensive background in medicine and pharmaceutical development. He completed his undergraduate studies at St. Joseph’s University, earning a Bachelor of Science degree in biology. He went on to obtain his medical degree from Drexel University College of Medicine and completed his residency in obstetrics and gynecology at Lehigh Valley Hospital.
With a strong clinical foundation, Dr. Tursi transitioned into the pharmaceutical industry, where he brought his medical expertise to various leadership roles. Before joining Endo International, he held significant positions at companies like Aralez Pharmaceuticals, where he was the Chief Medical Officer. He also worked with companies such as Innocoll Holdings PLC and Auxilium Pharmaceuticals in key roles that involved clinical development, medical affairs, and strategic planning.
Dr. Tursi is recognized for his contributions to advancing medical research and development across different therapeutic areas. His leadership at Endo International focuses on driving innovation and overseeing the company's medical and clinical development strategies. His professional journey reflects a commitment to enhancing patient care through the development of effective pharmaceutical solutions.
Mark T. Bradley is an accomplished executive known for his significant contributions to the financial sector, particularly within the pharmaceutical and healthcare industry. He serves as the Executive Vice President and Chief Financial Officer (CFO) of Endo International PLC, a prominent global specialty pharmaceutical company. In his role as CFO, Bradley is responsible for overseeing Endo's financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. His leadership plays a critical role in guiding the company's financial strategy, ensuring robust financial performance, and maintaining strong relationships with stakeholders and investors. Prior to his tenure at Endo International, Mark T. Bradley amassed extensive experience in finance and executive leadership, working with various major companies in the pharmaceutical and other industries. This wealth of experience provided him with a deep understanding of financial management, strategic planning, and operational excellence. Throughout his career, Bradley has been recognized for his strategic insight, dedication, and ability to drive financial stability and growth in complex environments, making him a valuable asset to Endo International PLC.
In his role as CFO, Bradley is responsible for overseeing Endo's financial operations, including financial planning and analysis, accounting, tax, treasury, and investor relations. His leadership plays a critical role in guiding the company's financial strategy, ensuring robust financial performance, and maintaining strong relationships with stakeholders and investors.
Prior to his tenure at Endo International, Mark T. Bradley amassed extensive experience in finance and executive leadership, working with various major companies in the pharmaceutical and other industries. This wealth of experience provided him with a deep understanding of financial management, strategic planning, and operational excellence.
Throughout his career, Bradley has been recognized for his strategic insight, dedication, and ability to drive financial stability and growth in complex environments, making him a valuable asset to Endo International PLC.
Frank B. Raciti is a notable figure in the pharmaceutical and corporate world, primarily recognized for his role at Endo International PLC. As an accomplished executive, Raciti has held the position of Executive Vice President, Quality, at Endo. His responsibilities have included overseeing and ensuring the quality and compliance of Endo's diverse range of pharmaceutical products. Raciti's career spans several decades in the industry, where he has built a reputation for excellence in quality assurance and regulatory affairs. At Endo, he has been instrumental in implementing strategic initiatives to enhance product quality and optimize manufacturing processes, ensuring that Endo meets the stringent standards set by regulatory bodies. His leadership has been crucial in navigating complex compliance landscapes while fostering a culture of continuous improvement within the organization. Before joining Endo, Raciti brought with him a wealth of experience from previous roles in which he demonstrated a strong commitment to quality and operational excellence. His educational background and professional affiliations reflect his dedication to advancing pharmaceutical quality standards and ensuring the safety and efficacy of healthcare products.
Raciti's career spans several decades in the industry, where he has built a reputation for excellence in quality assurance and regulatory affairs. At Endo, he has been instrumental in implementing strategic initiatives to enhance product quality and optimize manufacturing processes, ensuring that Endo meets the stringent standards set by regulatory bodies. His leadership has been crucial in navigating complex compliance landscapes while fostering a culture of continuous improvement within the organization.
Before joining Endo, Raciti brought with him a wealth of experience from previous roles in which he demonstrated a strong commitment to quality and operational excellence. His educational background and professional affiliations reflect his dedication to advancing pharmaceutical quality standards and ensuring the safety and efficacy of healthcare products.
Laure E. Park served as the Senior Vice President of Investor Relations and Corporate Affairs at Endo International PLC. In this role, she was responsible for managing and overseeing the company's investor relations strategies, corporate communications, and public affairs activities. With extensive experience in the pharmaceutical and healthcare sectors, she played a vital role in communicating Endo's financial performance and strategic initiatives to investors, analysts, and other key stakeholders. Her work involved shaping the company's messaging and ensuring transparency and clarity in its communications. Park brought significant expertise and leadership in managing company reputation and relations with the investment community.
Patrick A. Barry is a well-regarded business executive who serves as the Executive Vice President and Chief Commercial Officer at Endo International PLC. With a robust background in pharmaceuticals and commercial strategy, Mr. Barry brings extensive experience in formulating and executing business plans that drive growth and innovation within the company. At Endo International, he is responsible for overseeing commercial operations, which include marketing, sales, and product management across Endo's diverse portfolio. His strategic vision has been instrumental in enhancing the company's market presence and expanding its product offerings. Prior to his current role, Mr. Barry has held various leadership positions in the pharmaceutical industry, demonstrating a consistent track record of success in high-impact roles. Mr. Barry's leadership style is characterized by his focus on fostering collaboration and encouraging innovative approaches to addressing market challenges. His contributions have significantly shaped the company's strategic direction, ensuring alignment with its core values and long-term objectives.
At Endo International, he is responsible for overseeing commercial operations, which include marketing, sales, and product management across Endo's diverse portfolio. His strategic vision has been instrumental in enhancing the company's market presence and expanding its product offerings. Prior to his current role, Mr. Barry has held various leadership positions in the pharmaceutical industry, demonstrating a consistent track record of success in high-impact roles.
Mr. Barry's leadership style is characterized by his focus on fostering collaboration and encouraging innovative approaches to addressing market challenges. His contributions have significantly shaped the company's strategic direction, ensuring alignment with its core values and long-term objectives.
